REIN SARAL, M. D.; RICHARD F. AMBINDER, M.D.; WILLIAM H. BURNS, M.D.; CHRIS M. ANGELOPULOS, P.A.; DIANE E. GRIFFIN, M.D., Ph.D.; PHILIP J. BURKE, M.D.; PAUL S. LIETMAN, M.D., Ph.D.
Twenty-nine adult patients with acute leukemia receiving timed sequential chemotherapy participated in a randomized, double-blind, placebo-controlled trial of acyclovir prophylaxis against reactivated herpes simplex virus infection. Patients with pretreatment antibody titers of 1:16 or greater received acyclovir or placebo starting 4 days after their initial chemotherapy. Treatment was given either for 32 days or until the patients were discharged from the hospital or until a culture-positive herpes simplex virus infection was found. Culture-positive herpes simplex virus infection developed in 11 of 15 patients who received placebo. No infection appeared in 14 patients who received acyclovir (p < 0.00005). No obvious acute drug toxicity was seen. Recurrent infection was seen in 6 of 14 patients after cessation of acyclovir when retreated with chemotherapy, suggesting no effect on viral latency in these 6 patients. Acyclovir provided highly effective prophylaxis against reactivated herpes simplex virus infections in adult patients with acute leukemia receiving timed sequential chemotherapy.
Learn more about subscription options.
Register Now for a free account.
SARAL R, AMBINDER RF, BURNS WH, ANGELOPULOS CM, GRIFFIN DE, BURKE PJ, et al. Acyclovir Prophylaxis Against Herpes Simplex Virus Infection in Patients with Leukemia: A Randomized, Double-Blind, Placebo-Controlled Study. Ann Intern Med. 1983;99:773-776. doi: 10.7326/0003-4819-99-6-773
Download citation file:
Published: Ann Intern Med. 1983;99(6):773-776.
Hematology/Oncology, Infectious Disease, Leukemia/Lymphoma.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only